RxDoctor Payments Data

Mary van Hal, MD

Internal Medicine · Keller, TXNPI 1902976442

Payments from drug & device makers

$6,970in general payments, 2019–2025

Across 421 payments — averaging $16.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$819
  • Pfizer$796
  • Lilly USA, LLC$671
  • AbbVie$632
  • Boehringer Ingelheim$607
  • AstraZeneca$452
  • plus $3K from 47 others

What the payments were for

  • Food & beverage$6,85098%
  • Education$1202%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,970 in reported general payments places this provider in the 90th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$103,527
Medicare patients
358
Services billed
2,190

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide135$145,533
JardianceEmpagliflozin106$112,865
EliquisApixaban57$73,019
MounjaroTirzepatide60$69,697
FarxigaDapagliflozin Propanediol48$46,655
TrulicityDulaglutide28$37,410
XareltoRivaroxaban30$36,366
Tresiba Flextouch U-200Insulin Degludec12$26,057
ProliaDenosumab14$24,271
JanuviaSitagliptin Phosphate17$22,661
MyrbetriqMirabegron27$22,440
LinzessLinaclotide16$21,079
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen560$14,950
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog17$14,361
TrintellixVortioxetine Hydrobromide17$12,743

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$819$145,533135 claims
Boehringer IngelheimJardiance$607$112,865106 claims
Lilly USA, LLCMounjaro, Trulicity$671$107,10788 claims
PfizerEliquis, Paxlovid$796$75,81374 claims
AstraZenecaFarxiga, Symbicort$452$53,15067 claims
AbbVieLinzess, Savella, Synthroid, Armour Thyroid$632$38,485124 claims
Johnson & JohnsonXarelto$178$36,36630 claims
AmgenProlia$220$24,27114 claims
MerckJanuvia$91$22,66117 claims
Astellas Pharma US IncMyrbetriq$257$22,44027 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$99$12,74317 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in Keller

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →